TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL DRUG SCREENING MARKET,BY PRODUCT AND SERVICE
6.1. Overview
6.2. Drug screening
6.3. Analytical Instruments
6.4. Rapid Testing Devices
6.5. Consumables
6.6. Drug Screening Service
7. GLOBAL DRUG SCREENING MARKET,BY SAMPLE TYPE
7.1. Overview
7.2. Urine samples
7.3. Breath Samples
7.4. Oral Fluid Samples
7.5. Hair Samples
7.6. Other Samples
8. GLOBAL DRUG SCREENING MARKET,BY END USER
8.1. Overview
8.2. Drug Testing Laboratories
8.3. Criminal Justice and Law Enforcement Agencies
8.4. Hospitals
8.5. Drug Treatment Centers
8.6. Individual Users
8.7. Pain Management Centers
8.8. Schools and Colleges
8.9. Workplaces
9. GLOBAL DRUG SCREENING MARKET, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Drug Screening Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Drug Screening Market,
10.7. Key developments and Growth Strategies
10.7.1. New ProductLaunch/Service Deployment
10.7.2. Merger &Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income,2022
10.8.2. Major Players R&D Expenditure.2022
11. COMPANY PROFILES
11.1. LabCorp (US)
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Quest Diagnostics (US)
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Abbott Laboratories (US)
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. OraSure Technologies (US)
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Alfa Scientific Designs (US)
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Thermeisher Scientific (US)
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Drägerwerk (Germany)
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. LifeLoc (US)
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. MPD Inc. (US)
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Omega Laboratories (US)
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Premier Biotech (US)
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Products Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Psychemedics (US)
11.12.1. Company Overview
11.12.2. Financial Overview
11.12.3. Products Offered
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Roche (Switzerland)
11.13.1. Company Overview
11.13.2. Financial Overview
11.13.3. Products Offered
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. Shimadzu (Japan)
11.14.1. Company Overview
11.14.2. Financial Overview
11.14.3. Products Offered
11.14.4. Key Developments
11.14.5. SWOT Analysis
11.14.6. Key Strategies
11.15. Siemens Healthineers (Germany)
11.15.1. Company Overview
11.15.2. Financial Overview
11.15.3. Products Offered
11.15.4. Key Developments
11.15.5. SWOT Analysis
11.15.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL DRUG SCREENING MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL DRUG SCREENING MARKET, ESTIMATES &FORECAST, 2018-2032(USD BILLION)
TABLE 3 GLOBAL DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL DRUG SCREENING MARKET,BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 5 GLOBAL DRUG SCREENING MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: DRUG SCREENING MARKET,BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: DRUG SCREENING MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 9 US: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 10 US: DRUG SCREENING MARKET,BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 11 US: DRUG SCREENING MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 12 CANADA: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 13 CANADA: DRUG SCREENING MARKET,BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 14 CANADA: DRUG SCREENING MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE , 2018-2032 (USD BILLION)
TABLE 3 EUROPE: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 4 GERMANY: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE,2018-2032 (USD BILLION)
TABLE 5 GERMANY: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 6 GERMANY: DRUG SCREENING MARKET, BY END USER , 2018-2032 (USD BILLION)
TABLE 7 FRANCE: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 8 FRANCE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 9 FRANCE: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 10 ITALY: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 11 ITALY: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 12 ITALY: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 13 SPAIN: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 14 SPAIN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 15 SPAIN: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 16 UK: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 17 UK: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 18 UK: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 25 JAPAN: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 26 JAPAN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 27 JAPAN: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 28 CHINA: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 29 CHINA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 30 CHINA: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 31 INDIA: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 32 INDIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 33 INDIA: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 34 AUSTRALIA: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 35 AUSTRALIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 36 AUSTRALIA: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 49 AFRICA: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 50 AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 51 AFRICA: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: DRUG SCREENING MARKET,BY PRODUCT AND SERVICE, 2018-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: DRUG SCREENING MARKET, BY END USER, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL DRUG SCREENING MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL DRUG SCREENING MARKET
FIGURE 4 GLOBAL DRUG SCREENING MARKET, SHARE (%), BY PRODUCT AND SERVICE, 2022
FIGURE 5 GLOBAL DRUG SCREENING MARKET, SHARE (%), BY SAMPLE TYPE, 2022
FIGURE 6 GLOBAL DRUG SCREENING MARKET, SHARE (%), BY END USER, 2022
FIGURE 7 GLOBAL DRUG SCREENING MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 NORTH AMERICA: DRUG SCREENING MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 EUROPE: DRUG SCREENING MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 ASIA-PACIFIC: DRUG SCREENING MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 REST OF THE WORLD: DRUG SCREENING MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 GLOBAL DRUG SCREENING MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 13 LABCORP (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 LABCORP (US): SWOT ANALYSIS
FIGURE 15 QUEST DIAGNOSTICS (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 QUEST DIAGNOSTICS (US):SWOT ANALYSIS
FIGURE 17 ABBOTT LABORATORIES (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 ABBOTT LABORATORIES (US):SWOT ANALYSIS
FIGURE 19 ORASURE TECHNOLOGIES (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 ORASURE TECHNOLOGIES (US):SWOT ANALYSIS
FIGURE 21 ALFA SCIENTIFIC DESIGNS (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 ALFA SCIENTIFIC DESIGNS (US):SWOT ANALYSIS
FIGURE 23 THERMEISHER SCIENTIFIC (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 THERMEISHER SCIENTIFIC (US):SWOT ANALYSIS
FIGURE 25 DRÄGERWERK (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 DRÄGERWERK (GERMANY): SWOT ANALYSIS
FIGURE 27 LIFELOC (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 LIFELOC (US): SWOT ANALYSIS
FIGURE 29 MPD INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 MPD INC. (US): SWOT ANALYSIS
FIGURE 31 OMEGA LABORATORIES (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 OMEGA LABORATORIES (US):SWOT ANALYSIS
FIGURE 33 PREMIER BIOTECH (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 PREMIER BIOTECH (US):SWOT ANALYSIS
FIGURE 35 PSYCHEMEDICS (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 PSYCHEMEDICS (US):SWOT ANALYSIS
FIGURE 37 ROCHE (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 ROCHE (SWITZERLAND): SWOT ANALYSIS
FIGURE 39 SHIMADZU (JAPAN): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 SHIMADZU (JAPAN): SWOT ANALYSIS
FIGURE 41 SIEMENS HEALTHINEERS (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 SIEMENS HEALTHINEERS (GERMANY): SWOT ANALYSIS
